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Abstract
Background There is increasing evidence that long-term complications in organic acidemias are caused by impaired mitochon-
drial metabolism. Currently, there is no specific biomarker to monitor mitochondrial dysfunction in organic acidemias. Serum
fibroblast growth factor 21 (FGF-21) is a biomarker for mitochondrial disease and could be a candidate to monitor mitochondrial
function in the deleterious course of disease.
Methods Data of 17 patients with classical organic acidemias (11 propionic acidemia (PA), four methylmalonic acidemia
(MMA) and two isovaleric acidemia (IVA) patients) were included. The clinical course was evaluated; metabolic decompensa-
tions and long-term complications were correlated with plasma FGF-21 levels. Cardiomyopathy, prolonged QT interval, renal
failure, and optic neuropathy were defined as long-term complications.
Results Patients ages ranged from 16 months up to 32 years. Serious long-term complications occurred in eight patients (five PA
and three MMA patients). In MMA and PA patients plasma FGF-21 levels during stable metabolic periods were significantly
higher in patients with long-term complications (Mdn = 2556.0 pg/ml) compared to patients without (Mdn = 287.0 pg/ml). A
median plasma FGF-21 level above 1500 pg/ml during a stable metabolic period, measured before the occurrence of long-term
complications, had a positive predictive value of 0.83 and a negative predictive value of 1.00 on long-term complications in
MMA and PA patients.
Conclusion This study demonstrates the potential role of FGF-21 as a biomarker for long-term complications in classical organic
acidemias, attributed to mitochondrial dysfunction.
Abbreviations
GDF-15 Growth differentiation factor 15
FGF-21 Fibroblast growth factor 21
IVA Isovaleric acidemia
MMA Methylmalonic acidemia
PA Propionic acidemia
RDA Recommended daily allowance
rτ Kendall’s tau rank correlation
WHO World Health Organization
Ws Wilcoxon rank sum tests
Introduction
The branched chain amino acids isoleucine, valine, and
leucine are essential nutrients for human growth and de-
velopment (Adibi 1976). The enzymes methylmalonyl-
CoA mutase , p rop iony l -CoA carboxy lase , and
isovaleryl-CoA dehydrogenase play pivotal roles in the
metabolism of these amino acids. Deficiencies of these
enzymes result in three classic organic acidemias,
methylmalonic acidemia (MMA; OMIM #251000,
#251100, #251110, #277400, #277410), propionic
acidemia (PA; OMIM #606054), and isovaleric acidemia
(IVA; OMIM #243500). MMA and PA are characterized
by the potent ia l ly lethal accumulat ion of toxic
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metabolites, mainly 2-methylcitric acid, malonic acid, and
propionyl-CoA (Kölker et al. 2003; Schwab et al. 2006).
The treatment mainly consists of protein reduction as
well as avoidance of catabolism, and survival has greatly
improved beyond childhood (Enns et al. 2007; Pena et al.
2012). However, the prognosis is still unsatisfactory with
a high rate of severe long-term complications, such as
renal failure, cardiac arrhythmias, cardiomyopathy, optic
nerve atrophy with vision loss, pancreatitis, and mental
retardation (Marquard et al. 2011; Sutton et al. 2012;
Baumgartner et al. 2014; Fraser and Venditti 2016). The
protein restricted diet may also cause complications, such
as failure to thrive (van der Meer et al. 1996; Yannicelli
et al. 2003). Mitochondrial dysfunction has been
established in the pathophysiology of all long-term com-
plications (Schwab et al. 2006; Chandler et al. 2009; de
Keyzer et al. 2009; Fragaki et al. 2011; Melo et al. 2011;
Wajner and Goodman 2011; Manoli et al. 2013; Baruteau
et al. 2014; Wilnai et al. 2014; Zsengeller et al. 2014;
Gallego-Villar et al. 2016; Erlich-Hadad et al. 2017).
Occurrence of mental retardation is most likely multifac-
torial, for example cerebral damage during decompensa-
tions with metabolic encephalopathy (Kölker et al. 2006a,
cerebral accumulation of toxic metabolites (Kölker et al.
2006b; Harting et al. 2008) and presumably mitochondri-
al dysfunction (Melo et al. 2011; Wajner and Goodman
2011) .
The demonstration of mitochondrial dysfunction is es-
sential to improve the understanding of long-term compli-
cations and could be of major importance to develop and
potentially evaluate (preventive) treatment strategies by
identifying risk groups. The most reliable available eval-
uation of mitochondrial dysfunction is histological and
biochemical assessment of a muscle biopsy. However,
muscle biopsies are considered invasive and not accept-
able for follow up of mitochondrial dysfunction over the
years. Current plasma biomarkers, such as creatine kinase,
lactate, pyruvate, alanine and proline levels, and the lac-
tate to pyruvate ratio, have a low sensitivity and specific-
ity (Mitochondrial Medicine Society's Committee on
Diagnosis, Haas RH, Parikh et al. 2008; Davis et al.
2013, 2016). Serum fibroblast growth factor 21 (FGF-
21) has been suggested as a biomarker for mitochondrial
disease. Serum FGF-21 is stable with respect to process-
ing and storage, has a higher specificity and sensitivity
compared to other biomarkers, and is fast and inexpensive
to determine (Suomalainen et al. 2011; Davis et al. 2013;
Suomalainen 2013; Kim and Lee 2014; Ji et al. 2015; Lee
2015; Lehtonen et al. 2016; Montero et al. 2016). We
studied the potential of serum FGF-21 measured in the
stable metabolic period as a biomarker for long-term com-
plications, attributed to mitochondrial failure, in patients
with organic acidemias.
Methods
Study design
A total of 17 patients (adults and children) attending the out-
patient clinic of the metabolic center of the Erasmus
University Medical Center, were selected. Thereafter FGF-
21 measurements were done in leftover plasma samples pre-
viously collected and stored in the laboratory biobank for
research purposes. Of the 17 patients included: 11 were
known with PA (cases 1–11), four with MMA (cases 12–
15), and two with IVA (cases 16 and 17). The clinical courses
and other laboratory findings were obtained from the medical
files. The study was assigned as non-Medical Research
Involving Human Subjects Act (WMO) by the Medical
Ethical Committee (METC) of the Erasmus University
Medical Center. Patients and/or parents of the patients gave
permission for publication of their anonymous clinical and
laboratory data. Patients and/or parents were informed and
aware of the use of leftover material for research to which
none objected. Cardiomyopathy, prolonged QT interval, renal
failure, and optic neuropathy were defined as long-term com-
plications. Severe mental retardation and growth failure were
not defined as long-term complications. A severe decompen-
sation was defined as a blood pH level below 7.1 and/or am-
monia levels above 400 μmol/L (Baumgartner et al. 2014).
Total protein intake was defined as natural plus synthetic pro-
tein intake.
Data and statistical analysis
For diagnostic purposes, propionyl-CoA carboxylase ac-
tivities were measured in fibroblasts at the Section
Genetic Metabolic Diseases of the Erasmus University
Medical Center, Rotterdam, The Netherlands. The
propionyl-CoA carboxylase activity measurement is based
upon the incorporation of 14C-labeled CO2 (given in the
form of 14C-labeled sodium carbonate) within the sub-
strate propionyl-CoA. The excess CO2 that was not incor-
porated was removed by acidification. At the same time,
the incorporation of CO2 was also measured with pyru-
vate and with methylcrotonoyl as the substrate. The
isovaleryl-CoA dehydrogenase activities were measured
in lymphocytes based upon the anaerobic electron transfer
flavoprotein fluorescence reduction assay at the
Laboratory for Genetic Metabolic Diseases, Academic
Medical Center, Amsterdam, The Netherlands. Serum
levels of FGF-21 were determined in duplicate using a
commercial ELISA kit (Millipore), which is also applied
in our diagnostic process. To establish reference ranges,
two hundred control subjects were studied, covering all
ages, including newborns. Positive controls were 50 pa-
tients with a mitochondrial disorder known with an
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increased plasma FGF-21 level. We established a refer-
ence range of 0–200 pg/ml for healthy subjects, which
coincides with that of Suomalainen et al. (2011). The
samples were measured in duplicate and no significant
differences between samples (inter-sample variability)
were found. Plasma FGF-21 levels up to 3000 pg/ml were
linear, and measurements were reproducible up to
4000 pg/ml. Plasma FGF-21 levels higher than 4000 pg/
ml were therefore cut off to a value of 4000 pg/ml. Total
protein intake estimated at several time points was based
on dietary prescription by a trained metabolic dietitian
during standard care, results were compared to the WHO
recommended daily allowance (RDA) (Joint FAO/WHO/
UNU Expert Consultation on Protein and Amino Acid
Requirements in Human Nutrition (2002: Geneva et al.
2007)). Plasma amino acid levels measured during the
standard of care were obtained from the medical records
to determine nutritional status, and based on reference
levels expressed as low (below normal reference level),
normal (within reference level) or elevated levels (above
reference level). The patients with MMA and PA were
selected to assess the association of plasma amino acid
levels and plasma FGF-21 levels. Data were summarized
by frequencies, median, and means with standard devia-
tion (SD). Normal distribution was examined by
Kolmogorov-Smirnov tests and quantile-quantile (Q-Q)
plots. Student’s t-tests were performed to compare means
in the case of Gaussian and Wilcoxon rank sum tests (Ws)
of non normal distributions. Pearson’s correlation coeffi-
cient was used to evaluate the correlation between two
Gaussian distributed continuous variables and Kendall’s
tau rank correlation (rτ) in the case of non normal distri-
butions. Paired sample t-tests were performed to compare
plasma FGF-21 levels in stable metabolic periods to levels
in decompensations within each patient. In analyzing pos-
itive predictive value, negative predictive value, and odds
ratios on the occurrence of long-term complications, we
included plasma FGF-21 measurements during stable met-
abolic periods prior to the development of long-term com-
plications in MMA and PA patients. In defining an opti-
mal cut off point value for FGF-21 we used a receiver
operating characteristic (ROC) curve (defining the plasma
FGF-21 level with optimal sensitivity and specificity).
Since protein restriction may infer FGF-21 increases,
and since especially leucine and methionine restriction
are associated with FGF-21 increase (Perez-Marti et al.
2016), Kendall’s tau rank correlation was calculated to
test the correlation of total protein intake and methionine
or leucine concentrations with plasma FGF-21 levels for
each patient individually. Furthermore, we tested the as-
sociation of other nutritional parameters, namely valine,
isoleucine, alanine, phenylalanine, proline, and threonine,
with plasma FGF-21 levels. P-values smaller than 0.05
were considered to indicate statistical significances.
SPSS data manager (version 24) was used for statistical
analyses.
Results
Description of the study population
Patient characteristics of all 17 patients with organic acidemia
are presented in Table 1. Four patients were diagnosed by
family or selective newborn screening and one patient was
diagnosed prenatally. Eight patients (six with PA and two with
MMA) presented in the neonatal period. Two of these patients
were initially on mechanical ventilation and one was dialyzed.
A total of four patients presented in childhood. These patients
presented either with complaints of vomiting, malaise, and
weight loss; with gastro-esophageal reflux, with encephalop-
athy or coma.
Sixteen patients showed a mild clinical course with no
severe decompensations after the initial presentation
(Table 1). One patient (case 10) died in the neonatal pe-
riod during the first severe decompensation due to a re-
fractory hemodynamic shock and hyperammonemia.
Despite good metabolic control, eight of the remaining
16 patients developed long-term complications (Table 2).
The mean age at the first long-term complication was
8.0 years (± SD: 3.4). Five PA patients developed cardiac
complications, four of them (cases 1, 2, 4, and 8) devel-
oped cardiomyopathy between 8 and 13 years of age. In
one patient (case 2) this was unexpected as she was diag-
nosed prenatally by selective screening and she always
showed good metabolic control. A rapidly progressive
dilated cardiomyopathy lead to cardiac failure and death
at eight years of age, four months after the diagnosis of
cardiomyopathy. Case 8 had mild cardiomyopathy, but
died during a severe metabolic decompensation at the
age of 12 years. One patient had prolonged QT interval
without signs of cardiomyopathy. Four patients developed
renal failure between the age of 11 months and 12 years
of age. Two patients developed optic neuropathy, both at
the age of 16 years. One of them was also known with
reduced left ventricular function, and the other patient was
already known with renal failure.
Overview of FGF-21 levels and long-term
complications
A total of 62 FGF-21 measurements were performed in the 17
patients. Plasma FGF-21 levels were determined before the
onset of long-term complications in seven of the eight patients
with long-term complications (Fig. 1a). In the remaining pa-
tient, FGF-21 measurements were performed in samples
J Inherit Metab Dis
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obtained after long-term complications had occurred (Fig. 1a).
All FGF-21 levels from samples retrieved before long-term
complications developed, were elevated (Fig. 1a). In two pa-
tients (cases 1 and 2), plasma FGF-21 levels were already
elevated, up to ten times the upper level of normal, from the
neonatal period onward and remained at the same level with
older age. In one patient (case 3), plasma FGF-21 levels in-
creased rapidly from the neonatal period up to eight months of
age and remained high thereafter. In another patient (case 8),
plasma FGF-21 levels were extremely high before complica-
tions and decreased thereafter, as previously mentioned, she
eventually died of dilated cardiomyopathy. One patient (case
11) demonstrated high plasma FGF-21 levels during stable
disease, at that time point without long-term complications.
In an IVA patient without long-term complications (case 16),
the highly elevated plasma FGF-21 levels taken during a met-
abolic decompensation normalized thereafter (Fig. 1b).
In MMA and PA patients, median plasma FGF-21 levels
(of each patient) during stable metabolic periods were signif-
icantly higher in patients with long-term complications during
follow up (median FGF-21 = 2556.0 pg/ml) compared to
those who did not develop complications (median FGF-21 =
287.0 pg/ml) (Ws = 29.00, Z = −2.066, p = 0.039) (Fig. 2a). In
MMA and PA patients, the individual mean plasma FGF-21
levels during stable metabolic periods (M = 2600, SD = 843)
did not differ from the individual median plasma FGF-21
levels during decompensations (M = 2309, SD = 619) (t(6) =
0.566, p = 0.592). None of the patients with a median plasma
FGF-21 below 1500 pg/ml during the stable metabolic period
(n = 5) developed long term complications. All, but one pa-
tient, developed long-term complications in those with a me-
dian plasma FGF-21 above 1500 pg/ml (n = 5) (samples taken
during a stable metabolic period prior to the occurrence of
long-term complications) in MMA and PA patients (Suppl.
Fig. 1). A median plasma FGF-21 level above 1500 pg/ml
during a stable metabolic period, measured before the occur-
rence of long-term complications, has a positive predictive
value of 0.83 on long-term complications and a negative pre-
dictive value of 1.00 in MMA and PA patients.
Renal function and FGF-21
Plasma creatinine levels did not correlate with plasma FGF-21
levels within the individual patient; nor did the median plasma
FGF-21 level of each patient correlate with the median plasma
creatinine level of each patient.
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define the different patients. Vertical gapped line indicates the occurrence of first complication (Fig. 1a)
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Protein restriction and FGF-21
Total protein intake (g/kg/day) did not correlate with plasma
FGF-21 levels in any patient, nor did median total protein
intake (of each patient) correlate with median plasma FGF-
21 levels (of each patient). Furthermore, total protein intake as
%RDAwas not associated with plasma FGF-21 levels, except
in one patient (case 3) (rτ(9) = 0.957, p < 0.001) (Suppl.
Fig. 2). In MMA and PA, plasma valine levels were low in
the majority of the patients (Suppl. Fig. 3). In MMA and PA,
plasma FGF-21 levels were not lower in patients with low
plasma amino acids levels; valine, isoleucine, leucine, methi-
onine, threonine, alanine, phenylalanine, and proline, respec-
tively (Suppl. Fig. 3). Individual plasma amino acid levels
were not associated with plasma FGF-21 levels, except for
one patient (case 16). In this patient, all three branched chain
amino acids (BCAA) were associated with plasma FGF-21
levels (valine (r(8) = −0.643, p = 0.026), isoleucine (r(8) =
−0.618, p = 0.034), leucine (r(8) = −0.618, p = 0.034)).
Age, height, and FGF-21
There is no clear association of plasma FGF-21 levels and age
of the patient, in patients with long-term complications (data
not shown) as well as in patients without long-term complica-
tions (Fig. 1b). In 16 of 17 patients, growth charts were avail-
able. Six out of these 16 patients had moderate to severe
growth retardation (Table 2). In all of the patients, height z-
score did not correlate with plasma FGF-21 levels. The medi-
an plasma FGF-21 levels did not differ significantly in patients
with growth retardation (z-score < -2SD) compared to patients
without growth retardation (data not shown).
Discussion
This study demonstrates that FGF-21 can be a biomarker for
long-term complications, attributed to mitochondrial dysfunc-
tion, in classic organic acidemia patients. Plasma FGF-21
levels were high in stable metabolic periods in patients with
long-term complications, this was well before the onset of
these complications. A median plasma FGF-21 level above
1500 pg/ml during a stable metabolic period, measured before
the occurrence of long-term complications, had a positive pre-
dictive value of 0.83 on long-term complications, a negative
predictive value of 1.00, and an odds ratio of 5.0. Plasma
FGF-21 levels were not associated with growth, nutritional
status or renal function.
Our results give additional proof to the hypothesis that
mitochondrial dysfunction plays a role in long-term compli-
cations in classical organic acidemia patients (Wajner et al.
2004; Schwab et al. 2006; Chandler et al. 2009; de Keyzer
et al. 2009; Fragaki et al. 2011; Melo et al. 2011; Wajner and
Goodman 2011; Manoli et al. 2013; Baruteau et al. 2014;
Gallego-Villar et al. 2014; Wilnai et al. 2014; Zsengeller et
al. 2014; Gallego-Villar et al. 2016; Rivera-Barahona et al.
2017). Plasma FGF-21 levels were high in PA patients before
they developed long-term complications, both before severe
complications (such as lethal cardiomyopathy) and before
milder complications (prolonged QT interval and slight left
ventricular hypertrophy). Our observation of high plasma
FGF-21 levels in a patient with QT prolongation, suggesting
a role of mitochondrial dysfunction, is in line with
Baumgartner et al. (2007). In MMA, the renal complications
and the high plasma FGF-21 levels could point toward a role
of mitochondrial dysfunction in renal failure, which was also
proposed by others (Manoli et al. 2013). Kölker et al have
suggested that mitochondrial dysfunction is not caused by a
direct toxicity of methylmalonic acid but by inhibition of the
respiratory chain by 2-methylcitric acid, malonic acid, and
propionyl-CoA, which are increased in MMA as well
(Kölker et al. 2003). Furthermore, plasma FGF-21 levels can
be elevated in chronic as well as acute kidney disease and an
association between plasma FGF-21 levels and estimated glo-
merular filtration rate has been found in non OAD patients
(Hindricks et al. 2014). In our patient population we did not
observe an association between plasma FGF-21 levels and
renal function plasma (creatinine levels). Furthermore, plasma
FGF-21 levels were already elevated before the occurrence of
kidney failure, nor was there an increase in plasma FGF-21
levels when renal function deteriorated.
In stable metabolic periods there is a clear difference in
plasma FGF-21 levels in patients with long-term complica-
tions compared to those without. Importantly, in this patient
cohort the majority of long-term complications occurred be-
tween 7 and 9 years of age. This suggests that by determina-
tion of plasma FGF-21 levels in the stable metabolic period in
early childhood we can potentially identify risk groups for
long-term complications. In the stable metabolic period, only
one patient (case 11) had high plasma FGF-21 levels without
long-term complications. This patient had his latest visit at the
age of 4 years and based on our results and the occurrence of
long-term complications mainly between 7 and 9 years of age,
this patient can be identified as a potential risk patient for
long-term complications. During decompensation, one patient
(case 16) had a severe increase in plasma FGF-21 levels,
which normalized thereafter. The high plasma FGF-21 levels
in this case, could be due to either the decompensation itself or
the increased rigorousness of protein restriction; the last was
also reflected by the decreased plasma BCAA levels observed
during this decompensation. Based on our results, we recom-
mend measuring plasma FGF-21 levels in stable metabolic
periods. A median plasma FGF-21 level above 1500 pg/ml
measured during a stable metabolic period, before the occur-
rence of long-term complications, seems to predict long-term
complications. The negative predictive value of 1.00 observed
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in this patient cohort should be interpreted with respect to the
follow-up time and the fact that long-term complications can
occur at later disease stage.
A total of three patients had died, one during the neonatal
period (case 10), the others at the age of 8 (case 2) and 12 years
(case 8) respectively. Case 8 had initially highly elevated plas-
ma FGF-21 levels in stable conditions, which decreased over
the years until the patient died due to lethal cardiomyopathy.
This decrease in plasma FGF-21 plasma levels might be the
consequence of the potentially lethal mitochondrial
dysfunction.
In none of the MMA and PA patients, an association be-
tween plasma FGF-21 levels and nutritional status, with re-
spect to protein intake and plasma levels of BCAA, alanine,
phenylalanine, methionine, threonine, and proline, was found.
There are some potential limitations of this study. Firstly, a
retrospective study design cannot make causal inferences and
therefore a prospective study is required to confirm our obser-
vations. Secondly, this retrospective design could lead to a
selection bias and the relatively small number of patients stud-
ied could lead to low internal validity.
This study provides a first insight into a potential bio-
marker for long-term complications in organic acidemias.
Long-term complications occur despite good metabolic
control (Ianchulev et al. 2003; de Keyzer et al. 2009).
We suggest that mitochondrial dysfunction is an ongoing
process independent of metabolic control. It is important
to focus on the role of preventive treatment strategies. A
potential preventive therapy is anti-oxidants administra-
tion. To date, the beneficial efficacy of anti-oxidant ther-
apies varies, ranging from improvement of long-term
complications to no beneficial effect (Baruteau et al.
2014; Gallego-Villar et al. 2014; Martinez Alvarez et al.
2016; Rivera-Barahona et al. 2017). Absence of therapy
efficacy can be due to the relatively late initiation of anti-
oxidants in disease progression. First, the results observed
in this study, namely the association between plasma
FGF-21 levels and the occurrence of long-term complica-
tions as well as the high positive and negative predictive
value of a median plasma FGF-21 level above 1500 pg/
ml, should be replicated in another cohort of classical
organic acidemia patients. Other biomarkers for mito-
chondrial dysfunction, like growth differentiation factor
15 (GDF-15), should be included in order to identify their
role and relation with the occurrence of long-term com-
plications in these disorders and compare them to plasma
FGF-21. Once the FGF-21 results are confirmed and the
role of GDF-15 established, further research should deter-
mine if FGF-21 or other mitochondrial markers could play
a role in the evaluation of preventive strategies
concerning the consequences of mitochondrial impair-
ment, and if FGF-21 plays a pathogenic role in the devel-
opment of mitochondrial impairment.
Conclusion
This study provides new insights into the potential role of
FGF-21 as a biomarker for predicting long-term complica-
tions in organic acidemias. Increased plasma FGF-21 levels
and long-term complications are attributable to mitochondrial
dysfunction. Further research should be performed in another
cohort of patients to verify our observations and to investigate
the potential role of FGF-21 as a biomarker of (preventive)
treatment efficacy.
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